Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥208.00 - ¥648.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥33.35B
Enterprise Value¥38.92K
Total Cash (Recent Filing)¥10.87B
Total Debt (Recent Filing)¥2.59B
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 12, 2026EPS Estimate
-2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.18
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-36.5
Revenue Forecast (FY)¥427.75M
Bulls Say, Bears Say
Bulls Say
Improved Leverage And Equity CushionMaterial reduction in leverage and a larger equity base provide a meaningful capital cushion. Lower debt-to-equity reduces near-term refinancing risk and gives management durable flexibility to fund clinical programs, pursue partnerships or absorb setbacks without immediate distress.
Partnering/licensing-focused Business ModelA business model centered on partnering and licensing suits development-stage cell therapy firms: it preserves cash, leverages external commercialization capabilities, and can accelerate market access for niche regenerative products while limiting standalone commercialization burdens.
Trailing Improvement In Free Cash Flow TrendA positive growth rate in free cash flow on a trailing basis suggests the company may be slowing burn or improving cash conversion. Sustained improvement would extend runway and reduce reliance on frequent financing, enabling steadier progress through clinical milestones.
Bears Say
Heavy Negative Operating And Free Cash FlowPersistently large negative operating and free cash flows indicate the business consumes significant capital to advance programs. Over months this necessitates external financing or dilutive licensing, raising execution risk and constraining strategic optionality absent durable cash-flow improvement.
Declining Revenue And Negative Gross ProfitSharply shrinking revenue and a shift to negative gross profit erode the foundation for scalable commercialization. This structural weakness suggests current product or collaboration revenues are insufficient to cover costs, complicating paths to sustainable margins and self-funded growth.
Persistent Unprofitability And Weak ReturnsOngoing net losses and a negative TTM ROE reflect persistent value erosion. Over the medium term this depletes equity, increases cost of capital, and limits the company's ability to attract non-dilutive funding or favorable partnership terms without meaningful operational or clinical inflection.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥208.00 and its highest was ¥648.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥33.35B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is Aug 12, 2026 which is tomorrow.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on May 14, 2026. The company reported -¥27.65 earnings per share for the quarter, missing the consensus estimate of -¥11.14 by -¥16.51.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Overvalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -2.43.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of -¥27.65 in its last earnings report, missing expectations of -¥11.14. Following the earnings report the stock price went down -1.163%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―